nodes	percent_of_prediction	percent_of_DWPC	metapath
Tadalafil—CYP3A4—Cytarabine—lymphatic system cancer	0.0972	0.318	CbGbCtD
Tadalafil—CYP3A4—Teniposide—lymphatic system cancer	0.0957	0.313	CbGbCtD
Tadalafil—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0669	0.219	CbGbCtD
Tadalafil—CYP3A4—Vincristine—lymphatic system cancer	0.0461	0.151	CbGbCtD
Tadalafil—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.0025	0.0036	CcSEcCtD
Tadalafil—Dyspnoea—Teniposide—lymphatic system cancer	0.00247	0.00356	CcSEcCtD
Tadalafil—Oedema—Fludarabine—lymphatic system cancer	0.00244	0.00351	CcSEcCtD
Tadalafil—Infection—Fludarabine—lymphatic system cancer	0.00242	0.00349	CcSEcCtD
Tadalafil—Renal failure—Carmustine—lymphatic system cancer	0.0024	0.00346	CcSEcCtD
Tadalafil—Vomiting—Mechlorethamine—lymphatic system cancer	0.00239	0.00344	CcSEcCtD
Tadalafil—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00239	0.00344	CcSEcCtD
Tadalafil—Urinary tract infection—Carmustine—lymphatic system cancer	0.00238	0.00342	CcSEcCtD
Tadalafil—Rash—Mechlorethamine—lymphatic system cancer	0.00237	0.00342	CcSEcCtD
Tadalafil—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00237	0.00341	CcSEcCtD
Tadalafil—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00237	0.00341	CcSEcCtD
Tadalafil—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00236	0.00339	CcSEcCtD
Tadalafil—Flushing—Bleomycin—lymphatic system cancer	0.00233	0.00336	CcSEcCtD
Tadalafil—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.0023	0.00331	CcSEcCtD
Tadalafil—Myocardial infarction—Vincristine—lymphatic system cancer	0.00229	0.0033	CcSEcCtD
Tadalafil—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00227	0.00327	CcSEcCtD
Tadalafil—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.00226	0.00325	CcSEcCtD
Tadalafil—Bone disorder—Methotrexate—lymphatic system cancer	0.00224	0.00323	CcSEcCtD
Tadalafil—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00224	0.00323	CcSEcCtD
Tadalafil—Sweating—Vincristine—lymphatic system cancer	0.00224	0.00322	CcSEcCtD
Tadalafil—Renal failure—Mitoxantrone—lymphatic system cancer	0.00223	0.00322	CcSEcCtD
Tadalafil—Nausea—Mechlorethamine—lymphatic system cancer	0.00223	0.00322	CcSEcCtD
Tadalafil—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00223	0.00321	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00222	0.0032	CcSEcCtD
Tadalafil—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00221	0.00318	CcSEcCtD
Tadalafil—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00221	0.00318	CcSEcCtD
Tadalafil—Haemoglobin—Carmustine—lymphatic system cancer	0.00221	0.00318	CcSEcCtD
Tadalafil—Urticaria—Teniposide—lymphatic system cancer	0.0022	0.00317	CcSEcCtD
Tadalafil—Haemorrhage—Carmustine—lymphatic system cancer	0.00219	0.00316	CcSEcCtD
Tadalafil—Abdominal pain—Teniposide—lymphatic system cancer	0.00219	0.00316	CcSEcCtD
Tadalafil—Paraesthesia—Fludarabine—lymphatic system cancer	0.00219	0.00315	CcSEcCtD
Tadalafil—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00218	0.00315	CcSEcCtD
Tadalafil—Sweating—Mitoxantrone—lymphatic system cancer	0.00218	0.00314	CcSEcCtD
Tadalafil—Dyspnoea—Fludarabine—lymphatic system cancer	0.00217	0.00313	CcSEcCtD
Tadalafil—Haematuria—Mitoxantrone—lymphatic system cancer	0.00217	0.00312	CcSEcCtD
Tadalafil—Oedema peripheral—Carmustine—lymphatic system cancer	0.00216	0.00312	CcSEcCtD
Tadalafil—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00216	0.00311	CcSEcCtD
Tadalafil—Dyspepsia—Fludarabine—lymphatic system cancer	0.00214	0.00309	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.0021	0.00303	CcSEcCtD
Tadalafil—Fatigue—Fludarabine—lymphatic system cancer	0.0021	0.00303	CcSEcCtD
Tadalafil—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00208	0.003	CcSEcCtD
Tadalafil—Pain—Fludarabine—lymphatic system cancer	0.00208	0.003	CcSEcCtD
Tadalafil—Constipation—Fludarabine—lymphatic system cancer	0.00208	0.003	CcSEcCtD
Tadalafil—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00207	0.00298	CcSEcCtD
Tadalafil—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00206	0.00297	CcSEcCtD
Tadalafil—Urethral disorder—Vincristine—lymphatic system cancer	0.00205	0.00296	CcSEcCtD
Tadalafil—Eye disorder—Carmustine—lymphatic system cancer	0.00205	0.00296	CcSEcCtD
Tadalafil—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00205	0.00295	CcSEcCtD
Tadalafil—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00205	0.00295	CcSEcCtD
Tadalafil—Hypersensitivity—Teniposide—lymphatic system cancer	0.00204	0.00294	CcSEcCtD
Tadalafil—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00204	0.00294	CcSEcCtD
Tadalafil—Flushing—Carmustine—lymphatic system cancer	0.00204	0.00293	CcSEcCtD
Tadalafil—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00203	0.00292	CcSEcCtD
Tadalafil—Asthenia—Teniposide—lymphatic system cancer	0.00199	0.00287	CcSEcCtD
Tadalafil—Pruritus—Teniposide—lymphatic system cancer	0.00196	0.00283	CcSEcCtD
Tadalafil—Cardiac disorder—Vincristine—lymphatic system cancer	0.00194	0.0028	CcSEcCtD
Tadalafil—Mental disorder—Carmustine—lymphatic system cancer	0.00192	0.00277	CcSEcCtD
Tadalafil—Cough—Bleomycin—lymphatic system cancer	0.00191	0.00275	CcSEcCtD
Tadalafil—Angiopathy—Vincristine—lymphatic system cancer	0.0019	0.00274	CcSEcCtD
Tadalafil—Diarrhoea—Teniposide—lymphatic system cancer	0.0019	0.00273	CcSEcCtD
Tadalafil—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00189	0.00272	CcSEcCtD
Tadalafil—Chest pain—Bleomycin—lymphatic system cancer	0.00186	0.00268	CcSEcCtD
Tadalafil—Myalgia—Bleomycin—lymphatic system cancer	0.00186	0.00268	CcSEcCtD
Tadalafil—Back pain—Carmustine—lymphatic system cancer	0.00185	0.00266	CcSEcCtD
Tadalafil—Discomfort—Bleomycin—lymphatic system cancer	0.00184	0.00265	CcSEcCtD
Tadalafil—Mental disorder—Vincristine—lymphatic system cancer	0.00184	0.00264	CcSEcCtD
Tadalafil—Vision blurred—Carmustine—lymphatic system cancer	0.0018	0.00259	CcSEcCtD
Tadalafil—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00179	0.00259	CcSEcCtD
Tadalafil—Oedema—Bleomycin—lymphatic system cancer	0.00179	0.00257	CcSEcCtD
Tadalafil—Infection—Bleomycin—lymphatic system cancer	0.00177	0.00256	CcSEcCtD
Tadalafil—Back pain—Vincristine—lymphatic system cancer	0.00176	0.00254	CcSEcCtD
Tadalafil—Vomiting—Teniposide—lymphatic system cancer	0.00176	0.00254	CcSEcCtD
Tadalafil—Asthenia—Fludarabine—lymphatic system cancer	0.00175	0.00252	CcSEcCtD
Tadalafil—Rash—Teniposide—lymphatic system cancer	0.00175	0.00252	CcSEcCtD
Tadalafil—Dermatitis—Teniposide—lymphatic system cancer	0.00175	0.00252	CcSEcCtD
Tadalafil—Headache—Teniposide—lymphatic system cancer	0.00174	0.0025	CcSEcCtD
Tadalafil—Pruritus—Fludarabine—lymphatic system cancer	0.00172	0.00248	CcSEcCtD
Tadalafil—Back pain—Mitoxantrone—lymphatic system cancer	0.00172	0.00248	CcSEcCtD
Tadalafil—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00167	0.00241	CcSEcCtD
Tadalafil—Hypotension—Bleomycin—lymphatic system cancer	0.00167	0.0024	CcSEcCtD
Tadalafil—Diarrhoea—Fludarabine—lymphatic system cancer	0.00167	0.0024	CcSEcCtD
Tadalafil—Convulsion—Carmustine—lymphatic system cancer	0.00166	0.00238	CcSEcCtD
Tadalafil—Hypertension—Carmustine—lymphatic system cancer	0.00165	0.00238	CcSEcCtD
Tadalafil—Nausea—Teniposide—lymphatic system cancer	0.00165	0.00237	CcSEcCtD
Tadalafil—Vertigo—Vincristine—lymphatic system cancer	0.00164	0.00236	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00163	0.00234	CcSEcCtD
Tadalafil—Chest pain—Carmustine—lymphatic system cancer	0.00163	0.00234	CcSEcCtD
Tadalafil—Myalgia—Carmustine—lymphatic system cancer	0.00163	0.00234	CcSEcCtD
Tadalafil—Paraesthesia—Bleomycin—lymphatic system cancer	0.0016	0.00231	CcSEcCtD
Tadalafil—Dyspnoea—Bleomycin—lymphatic system cancer	0.00159	0.00229	CcSEcCtD
Tadalafil—Convulsion—Vincristine—lymphatic system cancer	0.00158	0.00228	CcSEcCtD
Tadalafil—Hypertension—Vincristine—lymphatic system cancer	0.00157	0.00227	CcSEcCtD
Tadalafil—Oedema—Carmustine—lymphatic system cancer	0.00156	0.00225	CcSEcCtD
Tadalafil—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00156	0.00224	CcSEcCtD
Tadalafil—Myalgia—Vincristine—lymphatic system cancer	0.00155	0.00224	CcSEcCtD
Tadalafil—Cough—Mitoxantrone—lymphatic system cancer	0.00155	0.00223	CcSEcCtD
Tadalafil—Infection—Carmustine—lymphatic system cancer	0.00155	0.00223	CcSEcCtD
Tadalafil—Vomiting—Fludarabine—lymphatic system cancer	0.00155	0.00223	CcSEcCtD
Tadalafil—Convulsion—Mitoxantrone—lymphatic system cancer	0.00154	0.00222	CcSEcCtD
Tadalafil—Rash—Fludarabine—lymphatic system cancer	0.00154	0.00221	CcSEcCtD
Tadalafil—Dermatitis—Fludarabine—lymphatic system cancer	0.00153	0.00221	CcSEcCtD
Tadalafil—Hypertension—Mitoxantrone—lymphatic system cancer	0.00153	0.00221	CcSEcCtD
Tadalafil—Pain—Bleomycin—lymphatic system cancer	0.00153	0.0022	CcSEcCtD
Tadalafil—Headache—Fludarabine—lymphatic system cancer	0.00153	0.0022	CcSEcCtD
Tadalafil—Tachycardia—Carmustine—lymphatic system cancer	0.00152	0.00219	CcSEcCtD
Tadalafil—Chest pain—Mitoxantrone—lymphatic system cancer	0.00151	0.00218	CcSEcCtD
Tadalafil—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00151	0.00218	CcSEcCtD
Tadalafil—Myalgia—Mitoxantrone—lymphatic system cancer	0.00151	0.00218	CcSEcCtD
Tadalafil—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.0015	0.00216	CcSEcCtD
Tadalafil—Discomfort—Mitoxantrone—lymphatic system cancer	0.00149	0.00215	CcSEcCtD
Tadalafil—Oedema—Vincristine—lymphatic system cancer	0.00149	0.00214	CcSEcCtD
Tadalafil—Infection—Vincristine—lymphatic system cancer	0.00148	0.00213	CcSEcCtD
Tadalafil—Nervous system disorder—Vincristine—lymphatic system cancer	0.00146	0.0021	CcSEcCtD
Tadalafil—Hypotension—Carmustine—lymphatic system cancer	0.00146	0.0021	CcSEcCtD
Tadalafil—Oedema—Mitoxantrone—lymphatic system cancer	0.00145	0.00209	CcSEcCtD
Tadalafil—Nausea—Fludarabine—lymphatic system cancer	0.00145	0.00209	CcSEcCtD
Tadalafil—Infection—Mitoxantrone—lymphatic system cancer	0.00144	0.00207	CcSEcCtD
Tadalafil—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00144	0.00207	CcSEcCtD
Tadalafil—Shock—Mitoxantrone—lymphatic system cancer	0.00143	0.00205	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00142	0.00205	CcSEcCtD
Tadalafil—Urticaria—Bleomycin—lymphatic system cancer	0.00142	0.00204	CcSEcCtD
Tadalafil—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00141	0.00204	CcSEcCtD
Tadalafil—Insomnia—Carmustine—lymphatic system cancer	0.00141	0.00203	CcSEcCtD
Tadalafil—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00141	0.00203	CcSEcCtD
Tadalafil—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0014	0.00202	CcSEcCtD
Tadalafil—Paraesthesia—Carmustine—lymphatic system cancer	0.0014	0.00202	CcSEcCtD
Tadalafil—Hypotension—Vincristine—lymphatic system cancer	0.00139	0.002	CcSEcCtD
Tadalafil—Dyspnoea—Carmustine—lymphatic system cancer	0.00139	0.002	CcSEcCtD
Tadalafil—Somnolence—Carmustine—lymphatic system cancer	0.00139	0.002	CcSEcCtD
Tadalafil—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00136	0.00195	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00136	0.00195	CcSEcCtD
Tadalafil—Hypotension—Mitoxantrone—lymphatic system cancer	0.00135	0.00195	CcSEcCtD
Tadalafil—Insomnia—Vincristine—lymphatic system cancer	0.00135	0.00194	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00135	0.00194	CcSEcCtD
Tadalafil—Paraesthesia—Vincristine—lymphatic system cancer	0.00134	0.00193	CcSEcCtD
Tadalafil—Pain—Carmustine—lymphatic system cancer	0.00133	0.00192	CcSEcCtD
Tadalafil—Constipation—Carmustine—lymphatic system cancer	0.00133	0.00192	CcSEcCtD
Tadalafil—Breast disorder—Methotrexate—lymphatic system cancer	0.00133	0.00191	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00132	0.0019	CcSEcCtD
Tadalafil—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00132	0.0019	CcSEcCtD
Tadalafil—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0013	0.00188	CcSEcCtD
Tadalafil—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00129	0.00186	CcSEcCtD
Tadalafil—Somnolence—Mitoxantrone—lymphatic system cancer	0.00129	0.00186	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00129	0.00185	CcSEcCtD
Tadalafil—Fatigue—Vincristine—lymphatic system cancer	0.00128	0.00185	CcSEcCtD
Tadalafil—Asthenia—Bleomycin—lymphatic system cancer	0.00128	0.00185	CcSEcCtD
Tadalafil—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00128	0.00184	CcSEcCtD
Tadalafil—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00128	0.00184	CcSEcCtD
Tadalafil—Pain—Vincristine—lymphatic system cancer	0.00127	0.00183	CcSEcCtD
Tadalafil—Constipation—Vincristine—lymphatic system cancer	0.00127	0.00183	CcSEcCtD
Tadalafil—Pruritus—Bleomycin—lymphatic system cancer	0.00126	0.00182	CcSEcCtD
Tadalafil—Fatigue—Mitoxantrone—lymphatic system cancer	0.00125	0.0018	CcSEcCtD
Tadalafil—Pain—Mitoxantrone—lymphatic system cancer	0.00124	0.00179	CcSEcCtD
Tadalafil—Constipation—Mitoxantrone—lymphatic system cancer	0.00124	0.00179	CcSEcCtD
Tadalafil—Abdominal pain—Carmustine—lymphatic system cancer	0.00123	0.00178	CcSEcCtD
Tadalafil—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00122	0.00175	CcSEcCtD
Tadalafil—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00122	0.00175	CcSEcCtD
Tadalafil—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00119	0.00171	CcSEcCtD
Tadalafil—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00118	0.0017	CcSEcCtD
Tadalafil—Abdominal pain—Vincristine—lymphatic system cancer	0.00118	0.0017	CcSEcCtD
Tadalafil—Urticaria—Mitoxantrone—lymphatic system cancer	0.00115	0.00166	CcSEcCtD
Tadalafil—Hypersensitivity—Carmustine—lymphatic system cancer	0.00115	0.00166	CcSEcCtD
Tadalafil—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00115	0.00165	CcSEcCtD
Tadalafil—Vomiting—Bleomycin—lymphatic system cancer	0.00114	0.00164	CcSEcCtD
Tadalafil—Infestation NOS—Methotrexate—lymphatic system cancer	0.00113	0.00163	CcSEcCtD
Tadalafil—Infestation—Methotrexate—lymphatic system cancer	0.00113	0.00163	CcSEcCtD
Tadalafil—Rash—Bleomycin—lymphatic system cancer	0.00113	0.00162	CcSEcCtD
Tadalafil—Dermatitis—Bleomycin—lymphatic system cancer	0.00113	0.00162	CcSEcCtD
Tadalafil—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00112	0.00162	CcSEcCtD
Tadalafil—Asthenia—Carmustine—lymphatic system cancer	0.00112	0.00161	CcSEcCtD
Tadalafil—Renal failure—Methotrexate—lymphatic system cancer	0.00111	0.0016	CcSEcCtD
Tadalafil—Conjunctivitis—Methotrexate—lymphatic system cancer	0.0011	0.00159	CcSEcCtD
Tadalafil—Hypersensitivity—Vincristine—lymphatic system cancer	0.0011	0.00158	CcSEcCtD
Tadalafil—Sweating—Methotrexate—lymphatic system cancer	0.00109	0.00156	CcSEcCtD
Tadalafil—Haematuria—Methotrexate—lymphatic system cancer	0.00108	0.00156	CcSEcCtD
Tadalafil—Epistaxis—Methotrexate—lymphatic system cancer	0.00107	0.00154	CcSEcCtD
Tadalafil—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00107	0.00154	CcSEcCtD
Tadalafil—Asthenia—Vincristine—lymphatic system cancer	0.00107	0.00154	CcSEcCtD
Tadalafil—Diarrhoea—Carmustine—lymphatic system cancer	0.00107	0.00154	CcSEcCtD
Tadalafil—Nausea—Bleomycin—lymphatic system cancer	0.00106	0.00153	CcSEcCtD
Tadalafil—Asthenia—Mitoxantrone—lymphatic system cancer	0.00104	0.0015	CcSEcCtD
Tadalafil—Dizziness—Carmustine—lymphatic system cancer	0.00103	0.00149	CcSEcCtD
Tadalafil—Haemoglobin—Methotrexate—lymphatic system cancer	0.00102	0.00147	CcSEcCtD
Tadalafil—Diarrhoea—Vincristine—lymphatic system cancer	0.00102	0.00147	CcSEcCtD
Tadalafil—Haemorrhage—Methotrexate—lymphatic system cancer	0.00102	0.00146	CcSEcCtD
Tadalafil—Pharyngitis—Methotrexate—lymphatic system cancer	0.00101	0.00145	CcSEcCtD
Tadalafil—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.001	0.00145	CcSEcCtD
Tadalafil—Urethral disorder—Methotrexate—lymphatic system cancer	0.000996	0.00144	CcSEcCtD
Tadalafil—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000992	0.00143	CcSEcCtD
Tadalafil—Vomiting—Carmustine—lymphatic system cancer	0.000991	0.00143	CcSEcCtD
Tadalafil—Dizziness—Vincristine—lymphatic system cancer	0.000984	0.00142	CcSEcCtD
Tadalafil—Rash—Carmustine—lymphatic system cancer	0.000983	0.00142	CcSEcCtD
Tadalafil—Dermatitis—Carmustine—lymphatic system cancer	0.000982	0.00142	CcSEcCtD
Tadalafil—Headache—Carmustine—lymphatic system cancer	0.000977	0.00141	CcSEcCtD
Tadalafil—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000961	0.00138	CcSEcCtD
Tadalafil—Eye disorder—Methotrexate—lymphatic system cancer	0.00095	0.00137	CcSEcCtD
Tadalafil—Tinnitus—Methotrexate—lymphatic system cancer	0.000948	0.00137	CcSEcCtD
Tadalafil—Vomiting—Vincristine—lymphatic system cancer	0.000946	0.00136	CcSEcCtD
Tadalafil—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000943	0.00136	CcSEcCtD
Tadalafil—Rash—Vincristine—lymphatic system cancer	0.000938	0.00135	CcSEcCtD
Tadalafil—Dermatitis—Vincristine—lymphatic system cancer	0.000938	0.00135	CcSEcCtD
Tadalafil—Headache—Vincristine—lymphatic system cancer	0.000932	0.00134	CcSEcCtD
Tadalafil—Nausea—Carmustine—lymphatic system cancer	0.000926	0.00133	CcSEcCtD
Tadalafil—Angiopathy—Methotrexate—lymphatic system cancer	0.000922	0.00133	CcSEcCtD
Tadalafil—Vomiting—Mitoxantrone—lymphatic system cancer	0.000922	0.00133	CcSEcCtD
Tadalafil—Immune system disorder—Methotrexate—lymphatic system cancer	0.000918	0.00132	CcSEcCtD
Tadalafil—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000916	0.00132	CcSEcCtD
Tadalafil—Rash—Mitoxantrone—lymphatic system cancer	0.000914	0.00132	CcSEcCtD
Tadalafil—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000913	0.00132	CcSEcCtD
Tadalafil—Headache—Mitoxantrone—lymphatic system cancer	0.000908	0.00131	CcSEcCtD
Tadalafil—Mental disorder—Methotrexate—lymphatic system cancer	0.000891	0.00128	CcSEcCtD
Tadalafil—Nausea—Vincristine—lymphatic system cancer	0.000884	0.00127	CcSEcCtD
Tadalafil—Nausea—Mitoxantrone—lymphatic system cancer	0.000861	0.00124	CcSEcCtD
Tadalafil—Back pain—Methotrexate—lymphatic system cancer	0.000856	0.00123	CcSEcCtD
Tadalafil—Vision blurred—Methotrexate—lymphatic system cancer	0.000834	0.0012	CcSEcCtD
Tadalafil—Vertigo—Methotrexate—lymphatic system cancer	0.000795	0.00115	CcSEcCtD
Tadalafil—Cough—Methotrexate—lymphatic system cancer	0.000772	0.00111	CcSEcCtD
Tadalafil—Convulsion—Methotrexate—lymphatic system cancer	0.000767	0.0011	CcSEcCtD
Tadalafil—Myalgia—Methotrexate—lymphatic system cancer	0.000753	0.00109	CcSEcCtD
Tadalafil—Chest pain—Methotrexate—lymphatic system cancer	0.000753	0.00109	CcSEcCtD
Tadalafil—Arthralgia—Methotrexate—lymphatic system cancer	0.000753	0.00109	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000748	0.00108	CcSEcCtD
Tadalafil—Discomfort—Methotrexate—lymphatic system cancer	0.000744	0.00107	CcSEcCtD
Tadalafil—Infection—Methotrexate—lymphatic system cancer	0.000718	0.00103	CcSEcCtD
Tadalafil—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000708	0.00102	CcSEcCtD
Tadalafil—Skin disorder—Methotrexate—lymphatic system cancer	0.000702	0.00101	CcSEcCtD
Tadalafil—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000698	0.00101	CcSEcCtD
Tadalafil—Hypotension—Methotrexate—lymphatic system cancer	0.000675	0.000972	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000658	0.000948	CcSEcCtD
Tadalafil—Insomnia—Methotrexate—lymphatic system cancer	0.000653	0.000941	CcSEcCtD
Tadalafil—Paraesthesia—Methotrexate—lymphatic system cancer	0.000649	0.000934	CcSEcCtD
Tadalafil—Dyspnoea—Methotrexate—lymphatic system cancer	0.000644	0.000928	CcSEcCtD
Tadalafil—Somnolence—Methotrexate—lymphatic system cancer	0.000642	0.000925	CcSEcCtD
Tadalafil—Dyspepsia—Methotrexate—lymphatic system cancer	0.000636	0.000916	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000624	0.000898	CcSEcCtD
Tadalafil—Fatigue—Methotrexate—lymphatic system cancer	0.000623	0.000897	CcSEcCtD
Tadalafil—Pain—Methotrexate—lymphatic system cancer	0.000618	0.00089	CcSEcCtD
Tadalafil—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000591	0.000851	CcSEcCtD
Tadalafil—Urticaria—Methotrexate—lymphatic system cancer	0.000574	0.000827	CcSEcCtD
Tadalafil—Abdominal pain—Methotrexate—lymphatic system cancer	0.000571	0.000823	CcSEcCtD
Tadalafil—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000532	0.000767	CcSEcCtD
Tadalafil—Asthenia—Methotrexate—lymphatic system cancer	0.000518	0.000747	CcSEcCtD
Tadalafil—Pruritus—Methotrexate—lymphatic system cancer	0.000511	0.000736	CcSEcCtD
Tadalafil—Diarrhoea—Methotrexate—lymphatic system cancer	0.000494	0.000712	CcSEcCtD
Tadalafil—Dizziness—Methotrexate—lymphatic system cancer	0.000478	0.000688	CcSEcCtD
Tadalafil—Vomiting—Methotrexate—lymphatic system cancer	0.000459	0.000662	CcSEcCtD
Tadalafil—Rash—Methotrexate—lymphatic system cancer	0.000455	0.000656	CcSEcCtD
Tadalafil—Dermatitis—Methotrexate—lymphatic system cancer	0.000455	0.000655	CcSEcCtD
Tadalafil—Headache—Methotrexate—lymphatic system cancer	0.000452	0.000652	CcSEcCtD
Tadalafil—Nausea—Methotrexate—lymphatic system cancer	0.000429	0.000618	CcSEcCtD
